• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

非房室模型（NONMEM）教程第二部分：估计方法与高级示例。

NONMEM Tutorial Part II: Estimation Methods and Advanced Examples.

作者信息

Bauer Robert J

机构信息

Pharmacometrics R&D, ICON Clinical Research LLC, Gaithersburg, Maryland, USA.

出版信息

CPT Pharmacometrics Syst Pharmacol. 2019 Aug;8(8):538-556. doi: 10.1002/psp4.12422. Epub 2019 Jun 21.

DOI:10.1002/psp4.12422
PMID:31044558
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6709422/
Abstract

In this second tutorial on NONMEM, the examples of typical pharmacokinetic/pharmacodynamic modeling problems that occur in the pharmaceutical field will be presented, which the reader can use as a template for his or her own modeling endeavors. Each of the problems presented is challenging in some way, and the logic behind setting up each problem is discussed. Logical concepts of the problem itself as well as the technical aspect of how to set it up in NONMEM are described and demonstrated. The concepts behind the various estimation algorithms will first be described to allow the user a better understanding of how to use them.

摘要

在本关于NONMEM的第二篇教程中，将展示制药领域中出现的典型药代动力学/药效学建模问题的示例，读者可将其用作自身建模工作的模板。所呈现的每个问题在某种程度上都具有挑战性，并会讨论设置每个问题背后的逻辑。将描述并演示问题本身的逻辑概念以及如何在NONMEM中设置该问题的技术方面。将首先描述各种估计算法背后的概念，以便用户更好地理解如何使用它们。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf81/6709422/0abc79367a11/PSP4-8-538-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf81/6709422/d283c574ef01/PSP4-8-538-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf81/6709422/0abc79367a11/PSP4-8-538-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf81/6709422/d283c574ef01/PSP4-8-538-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf81/6709422/0abc79367a11/PSP4-8-538-g002.jpg

相似文献

1
NONMEM Tutorial Part II: Estimation Methods and Advanced Examples.非房室模型（NONMEM）教程第二部分：估计方法与高级示例。
CPT Pharmacometrics Syst Pharmacol. 2019 Aug;8(8):538-556. doi: 10.1002/psp4.12422. Epub 2019 Jun 21.
2
NONMEM Tutorial Part I: Description of Commands and Options, With Simple Examples of Population Analysis.NONMEM教程第一部分：命令和选项说明，附群体分析简单示例。
CPT Pharmacometrics Syst Pharmacol. 2019 Aug;8(8):525-537. doi: 10.1002/psp4.12404. Epub 2019 Jun 13.
3
Delay differential equations based models in NONMEM.基于 NONMEM 的时滞微分方程模型。
J Pharmacokinet Pharmacodyn. 2021 Dec;48(6):763-802. doi: 10.1007/s10928-021-09770-z. Epub 2021 Jul 23.
4
Tutorial for $DESIGN in NONMEM: Clinical trial evaluation and optimization.NONMEM 设计教程：临床试验评估与优化。
CPT Pharmacometrics Syst Pharmacol. 2021 Dec;10(12):1452-1465. doi: 10.1002/psp4.12713. Epub 2021 Oct 19.
5
Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM.Piraña 和 PCluster：NONMEM 的建模环境和集群基础设施。
Comput Methods Programs Biomed. 2011 Jan;101(1):72-9. doi: 10.1016/j.cmpb.2010.04.018. Epub 2010 Jun 2.
6
Particle Filters: A Hands-On Tutorial.粒子滤波器：实践教程。
Sensors (Basel). 2021 Jan 9;21(2):438. doi: 10.3390/s21020438.
7
A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.复杂药代动力学和药效学模型的群体分析方法及软件综述，并附实例
AAPS J. 2007 Mar 2;9(1):E60-83. doi: 10.1208/aapsj0901007.
8
Translational Metabolomics of Head Injury: Exploring Dysfunctional Cerebral Metabolism with Ex Vivo NMR Spectroscopy-Based Metabolite Quantification头部损伤的转化代谢组学：基于体外核磁共振波谱的代谢物定量分析探索脑代谢功能障碍
9
Comparing the performance of first-order conditional estimation (FOCE) and different expectation-maximization (EM) methods in NONMEM: real data experience with complex nonlinear parent-metabolite pharmacokinetic model.比较NONMEM中一阶条件估计（FOCE）和不同期望最大化（EM）方法的性能：复杂非线性母体-代谢物药代动力学模型的真实数据经验。
J Pharmacokinet Pharmacodyn. 2021 Aug;48(4):581-595. doi: 10.1007/s10928-021-09753-0. Epub 2021 Apr 21.
10
Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose.NONMEM 模型与仿真工作平台：Pirana、PsN 和 Xpose 使用教程。
CPT Pharmacometrics Syst Pharmacol. 2013 Jun 26;2(6):e50. doi: 10.1038/psp.2013.24.

引用本文的文献

1
Optimizing Early Ophthalmology Clinical Trials: Home OCT and Modeling Can Reduce Sample Size by 20% to 40.优化早期眼科临床试验：家庭光学相干断层扫描（OCT）和建模可将样本量减少20%至40%。
Transl Vis Sci Technol. 2025 Sep 2;14(9):2. doi: 10.1167/tvst.14.9.2.
2
A machine learning approach to population pharmacokinetic modelling automation.一种用于群体药代动力学建模自动化的机器学习方法。
Commun Med (Lond). 2025 Jul 31;5(1):327. doi: 10.1038/s43856-025-01054-8.
3
A semi-mechanistic population pharmacokinetic-pharmacodynamic model to assess downstream drug-target effects on erythropoiesis.
一个用于评估下游药物靶点对红细胞生成作用的半机制群体药代动力学-药效学模型。
J Pharmacokinet Pharmacodyn. 2025 Jul 24;52(4):42. doi: 10.1007/s10928-025-09990-7.
4
Pirana and Integrated PMX Tools, a Workbench for NONMEM, NLME, pyDarwin, and RsNLME.皮拉纳与集成式群体药代动力学工具，一款用于NONMEM、非线性混合效应模型、pyDarwin和RsNLME的工作台。
CPT Pharmacometrics Syst Pharmacol. 2025 Aug;14(8):1298-1309. doi: 10.1002/psp4.70067. Epub 2025 Jul 4.
5
Variability in Meropenem Distribution and Clearance in Children with Sepsis: Population-Based Pharmacokinetics with Assessment of Renal Biomarkers.脓毒症患儿美罗培南分布与清除的变异性：基于人群的药代动力学及肾脏生物标志物评估
Clin Pharmacokinet. 2025 May;64(5):769-777. doi: 10.1007/s40262-025-01495-3. Epub 2025 Apr 24.
6
Accuracy and precision analyses of single-time-point dosimetry utilising physiologically-based pharmacokinetic modelling and non-linear mixed-effects modelling.利用基于生理的药代动力学模型和非线性混合效应模型对单时间点剂量测定法进行准确性和精密度分析。
EJNMMI Phys. 2025 Mar 26;12(1):26. doi: 10.1186/s40658-025-00726-7.
7
A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic Modeling.药代动力学建模中处理低于定量下限的删失数据的实用方法。
CPT Pharmacometrics Syst Pharmacol. 2025 Jun;14(6):1042-1049. doi: 10.1002/psp4.70015. Epub 2025 Mar 11.
8
Defining preclinical efficacy with the DNAPK inhibitor AZD7648 in combination with olaparib: a minimal systems pharmacokinetic-pharmacodynamic model.用DNA依赖性蛋白激酶（DNAPK）抑制剂AZD7648联合奥拉帕利确定临床前疗效：一个最小系统药代动力学-药效学模型
J Pharmacokinet Pharmacodyn. 2025 Feb 17;52(2):17. doi: 10.1007/s10928-025-09962-x.
9
Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre Study.基线药物清除率可预测接受维多珠单抗治疗的炎症性肠病儿童的预后：VedoKids前瞻性多中心研究结果
Aliment Pharmacol Ther. 2025 Mar;61(6):1000-1010. doi: 10.1111/apt.18484. Epub 2025 Jan 15.
10
Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region.用于指导临床试验设计和监管决策的模型驱动药物发现与开发方法：中东和北非地区入门指南
Saudi Pharm J. 2024 Dec;32(12):102207. doi: 10.1016/j.jsps.2024.102207. Epub 2024 Nov 27.